Please login to the form below

Not currently logged in
Email:
Password:

Santarus adds two board members

Alessandro Della Chà and Dr Matthew Strobeck join US biopharma

Santarus has appointed Alessandro Della Chà and Dr Matthew Strobeck to its board of directors.

The appointments mean the US-based biopharma firm, which has products including Glumetza (metformin hydrochloride extended release tablets) and Cycloset (bromocriptine mesylate) tablets, has now increased its number of directors to nine.

“We welcome our new board members and look forward to drawing on their industry, business and corporate expertise as we continue to build Santarus into a premier specialty biopharmaceutical company,” said David Hale, chair of Santarus.

Della Chà has been a senior partner of Italian commercial law firm Studio Legale Edoardo Ricci e Associati, since 1997. He has also been co-managing director of the company since 2003. He currently also serves as a director of Cosmo Pharmaceuticals.

Dr Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management from 2008 to 2011. He currently serves as a member of the board of directors of Metabolix.

11th April 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....